<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189657</url>
  </required_header>
  <id_info>
    <org_study_id>AERO-R98</org_study_id>
    <nct_id>NCT00189657</nct_id>
  </id_info>
  <brief_title>5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Européenne de Recherche en Oncologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association Européenne de Recherche en Oncologie</source>
  <brief_summary>
    <textblock>
      The main objective of this randomized trial is to compare 5FU/LV (Mayo-Clinic regimen or
      LV5FU2) to LV5FU2 + irinotécan in patients with resected B2 and C rectal cancer. Preoperative
      radiotherapy is recommended but not mandatory. Main endpoint is disease free survival.
      Secondary endpoint are overall survival, time to local recurrence, time to distant
      metastases, and tolerance. A total of 600 patients will be included in the trial.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Cancer of the Rectum</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>5FU/LV Mayo Clinic or LV5FU2</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LV5FU2 + irinotecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  rectal adenocarcinoma

          -  R0 surgery

          -  T3, N0, M0 or T4, N0, M0 or N1,2, M0

          -  chemotherapy can be started within 8 weeks after surgery

          -  Age &gt; 18

          -  Performance status ECOG &lt; 3

          -  preoperative radiotherapy allowed

          -  preoperative chemotherapy with 5FU +/- LV allowed

          -  Neutrophiles &gt; 1 500/mm3; Pl. &gt; 100 000/mm3

          -  Transaminases &lt; 2 x UNL; Alcalines Phosphatases &lt; 2 x UNL; Bili &lt; 1.1 UNL

          -  creatininemia &lt; 120 µmol/l and/or clearance of creatininemia &gt; 60 ml/mn

          -  Written informed consent before inclusion

        Exclusion Criteria:

          -  postoperative radiotherapy

          -  Distant metastases

          -  Contraindication to any drug contained in the chemotherapy regimens

          -  Any serious active disease or co-morbid medical condition including digestive
             inflammatory disease

          -  Gilbert disease

          -  severe toxicity of radiotherapy

          -  Pregnancy or breast feeding

          -  Absence of contraception in non menopausal women

          -  Adult patient unable to give informed consent because of intellectual impairment

          -  Concomitant participation to another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Pascal Piedbois, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association Europeenne de Recherche en Oncologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry Andre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GERCOR - Multidisciplinary Oncology Cooperative Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Piolot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association Europeenne de Recherche en Oncologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel Achille, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GERCOR - Multidisciplinary Oncology Cooperative Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iradj Bobhani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Française de Cancérologie Digestive</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Yves Douillard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNICANCER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annie JOUHAUD</last_name>
    <phone>+ 33 1 43 77 72 10</phone>
    <email>annie.jouhaud@aero-eu.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>AERO</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Piedbois, MD</last_name>
      <phone>+ 33 1 49 81 25 82</phone>
      <email>pascal.piedbois@hmn.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

